Dev World Bioeth. 2023 Sep;23(3):220-228. doi: 10.1111/dewb.12359. Epub 2022 Jun 16.
Debates about what constitutes benefits in human research continue to be less informed due to a lack of empirical evidence from the developing world. This study aimed to explore what constitutes benefits in HIV vaccine trials in Tanzania and examine inherent ethical implications. A qualitative case study design was deployed and a total of 29 purposively selected study participants comprising of experienced researchers, institutional review board members and community advisory board members were included. Collected data were analyzed by thematic analysis aided by computer software: MAXQDA version 20.4.0. The study findings indicate that there is a growing appreciation of benefits beyond actual vaccines to include 1) capacity building at individual, community, institutional and regulatory levels; and 2) non-capacity building related benefits such as strengthened collaborations, ancillary care and employment opportunities. So, as the struggle for viable HIV vaccines continues, other benefits that have accrued from such trials are not to be blindsided especially for developing countries like Tanzania.
由于发展中国家缺乏实证证据，有关人类研究中何为受益的争论仍然知之甚少。本研究旨在探讨在坦桑尼亚的艾滋病毒疫苗试验中何为受益，并审视其中固有的伦理含义。采用了定性案例研究设计，总共纳入了 29 名经过精心挑选的研究参与者，包括有经验的研究人员、机构审查委员会成员和社区咨询委员会成员。通过计算机软件 MAXQDA 版本 20.4.0 对收集到的数据进行了主题分析。研究结果表明，人们越来越认识到受益不仅仅是实际疫苗，还包括 1）个人、社区、机构和监管层面的能力建设；和 2）与能力建设无关的受益，如加强合作、辅助护理和就业机会。因此，随着对可行的艾滋病毒疫苗的持续努力，特别是对于像坦桑尼亚这样的发展中国家来说，不应忽视从这些试验中获得的其他受益。
